Petros Pharmaceuticals, Inc. (NASDAQ:PTPI – Get Free Report)’s share price shot up 30.4% on Monday . The company traded as high as $0.44 and last traded at $0.42. 1,777,419 shares changed hands during trading, an increase of 222% from the average session volume of 551,506 shares. The stock had previously closed at $0.32.
Petros Pharmaceuticals Stock Performance
The stock has a market capitalization of $2.92 million, a P/E ratio of -0.06 and a beta of 2.12. The company has a current ratio of 1.40, a quick ratio of 1.26 and a debt-to-equity ratio of 0.71. The company has a 50-day moving average price of $0.34 and a two-hundred day moving average price of $0.48.
Petros Pharmaceuticals (NASDAQ:PTPI – Get Free Report) last issued its earnings results on Wednesday, August 14th. The company reported ($0.37) earnings per share for the quarter. The business had revenue of $1.42 million during the quarter.
About Petros Pharmaceuticals
Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).
Recommended Stories
- Five stocks we like better than Petros Pharmaceuticals
- Roth IRA Calculator: Calculate Your Potential Returns
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- What is a Stock Market Index and How Do You Use Them?
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- Comparing and Trading High PE Ratio Stocks
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Petros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.